Literature DB >> 1934588

Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

S V Kaveri1, G Dietrich, V Hurez, M D Kazatchkine.   

Abstract

Intravenous immunoglobulin (IVIg) therapy is increasingly used in autoimmune diseases. Although its efficacy has only been established in a few specific antibody-mediated autoimmune conditions, accumulating evidence on the regulatory role of circulating immunoglobulins in the selection of peripheral B cell repertoires makes it an attractive potential therapeutic option to clinical immunologists. This overview briefly discusses the current use of IVIg in human autoimmune diseases with a particular emphasis on the possible mechanisms by which IVIg could suppress pathological autoimmune responses.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1934588      PMCID： PMC1554132          DOI： 10.1111/j.1365-2249.1991.tb05794.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  58 in total

Review 1.  The role of somatic mutation of immunoglobulin genes in autoimmunity.

Authors:  A Davidson; R Shefner; A Livneh; B Diamond
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

2.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

3.  Expression of three cross-reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults.

Authors:  S Fong; P P Chen; T A Gilbertson; J R Weber; R I Fox; D A Carson
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

4.  Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.

Authors:  S B Clarkson; J B Bussel; R P Kimberly; J E Valinsky; R L Nachman; J C Unkeless
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

5.  Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function.

Authors:  F Uher; H B Dickler
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

6.  High dose intravenous gamma globulin for Felty's syndrome.

Authors:  F C Breedveld; A Brand; W G van Aken
Journal:  J Rheumatol       Date:  1985-08       Impact factor: 4.666

7.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

8.  Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood.

Authors:  P Imbach; H P Wagner; W Berchtold; G Gaedicke; A Hirt; P Joller; C Mueller-Eckhardt; B Müller; E Rossi; S Barandun
Journal:  Lancet       Date:  1985-08-31       Impact factor: 79.321

9.  Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

Authors:  M Iwata; T Shimozato; H Tokiwa; E Tsubura
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin.

Authors:  J B Bussel; C Cunningham-Rundles; C Abraham
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144
View more
  29 in total

1.  Normal IgG downregulates the intracellular superoxide level and attenuates migration and permeability in human aortic endothelial cells isolated from a hypertensive patient.

Authors:  Xiuqing Wang; Qianyu Wang; Zhongjie Sun
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.

Authors:  B J B Lewis; D Leontyev; A Neschadim; M Blacquiere; D R Branch
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

5.  Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin.

Authors:  M Toyoda; X Zhang; A Petrosian; O A Galera; S J Wang; S C Jordan
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

6.  Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system.

Authors:  L Persson; J Borén; A Nicoletti; G K Hansson; M Pekna
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

7.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

8.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

Authors:  T Vassilev; C Gelin; S V Kaveri; M T Zilber; L Boumsell; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

10.  Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.

Authors:  A A Pall; M Varagunam; D Adu; N Smith; N T Richards; C M Taylor; J Michael
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.